ArticleCureus2024
The Outcomes of IgA Nephropathy With Nephrotic Syndrome: A Clinicopathological Study From Northern India.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ultrasensitive Immunoassay Using a Novel Galactose-Deficient IgA1 Antibody and Its Clinical Application in the Diagnosis of IgAN.Kidney international reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Nephrotic syndrome, an unusual clinical presentation of IgA nephropathy (IgAN), occurs only in a few cases. The data regarding its clinical characteristics and treatment outcomes are lacking. Material and methods In this retrospective analysis, we reviewed kidney biopsies conducted between January 2007 and December 2018. All patients with biopsy-proven IgAN and clinical presentation of nephrotic syndrome were included. Results Sixty-seven (11.9%) out of 560 patients with primary IgAN had nephrotic syndrome as the first clinical presentation. On MEST-C scoring, the baseline estimated glomerular filtration rate (eGFR) was significantly lower in the presence of segmental sclerosis (S1) (p=0.04) and >25% tubular atrophy/interstitial fibrosis (T1/2) (p=0.004). With immunosuppression, complete remission (CR), partial remission (PR), and no response (NR) occurred in 28 (41.8%), 32 (47.8%), and 7 (10.4%) patients, respectively. During the median follow-up of 190 weeks, the median absolute change in eGFR was significant between CR and NR groups (p=0.002), and PR and NR groups (p=0.02); however, it was not significant between CR and PR groups (p=0.14). In the CR, PR, and NR groups, 9, 15, and 7 patients had eGFR losses of ≥15 ml/min (p=0.004). No patient in the CR group, one in the PR group, and three in the NR group progressed to end-stage kidney disease (ESKD) (p=0.003). Further, none of the MEST-C scores correlated with the clinical outcome parameters. Conclusion Immunosuppression in treating IgAN accompanied by nephrotic syndrome helps in proteinuria remission. Achieving remission, whether complete or partial, delays disease progression and improves renal survival. Moreover, the baseline eGFR was significantly lower when S1 and T1/2 lesions were present in kidney biopsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.